The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Is now the time to buy this exciting healthcare stock? The post Exciting clinical news for this ASX healthcare stock earns it a buy recommendation appeared first on The Motley Fool Australia.

Thank you for signing up! Did you know with an ad-lite subscription to Burnley Express, you get 70% fewer ads while viewing ...

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

After a routine blood test led to his diagnosis, the 70-year-old travel expert urges everyone to prioritize health exams.

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

A surgeon has explained the rules men need to follow before getting tested for cancer - if they want an accurate result.

We present the case of a patient with an elevated prostate-specific antigen level who underwent a prostate MRI that revealed a mass between the prostate and rectum, prompting further evaluation.

HIGHLIGHTS ...

Chronic hepatitis D virus (HDV) coinfection in people with chronic hepatitis B is associated with rapid progression to liver cirrhosis and high mortality. In 2020, the estimated global HDV burden ...

Epigenetic programming from prolonged undernutrition and terror can persist 3–4 generations, plausibly contributing to elevated cardiometabolic and mental health burdens documented among Irish cohorts ...

Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer inpatients to community dental providers. Objectives: Previous research suggests ...